Preferred Label : phenylbutyrates;
MeSH definition : Derivatives of 4-phenylbutyric acid, including its salts and esters.;
Is substance : O;
Origin ID : D010654;
UMLS CUI : C0031465;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
Record concept(s)
Related MeSH Supplementary Concept(s)
- HDAC-42 [MeSH Supplementary Concept]
- JE 2147 [MeSH Supplementary Concept]
- JE 533 [MeSH Supplementary Concept]
- KE 758 [MeSH Supplementary Concept]
- cafilon [MeSH Supplementary Concept]
Semantic type(s)
Derivatives of 4-phenylbutyric acid, including its salts and esters.
https://www.has-sante.fr/jcms/p_3576423/fr/pheburane-phenylbutyrate-de-sodium-desordres-du-cycle-de-l-uree
2025
false
false
false
France
pharmaceutical solutions
administration, oral
treatment outcome
insurance, health, reimbursement
sodium phenylbutyrate
4-phenylbutyric acid
carbamoyl-phosphate synthase i deficiency disease
citrullinemia
ornithine carbamoyltransferase deficiency disease
evaluation of the transparency committee
phenylbutyrates
4-phenylbutyric acid, sodium salt
---
https://www.has-sante.fr/jcms/p_3097607/fr/ravicti
2019
false
false
false
France
infant, newborn
administration, oral
glycerol phenylbutyrate
urea cycle disorders, inborn
treatment outcome
glycerol phenylbutyrate
evaluation of the transparency committee
phenylbutyrates
glycerol
glycerol
---
https://www.has-sante.fr/portail/jcms/c_2855997/fr/ravicti
https://www.has-sante.fr/portail/jcms/c_2855997/fr/ravicti-phenylbutyrate-de-glycerol-medicament-des-voies-digestives-et-du-metabolisme
2018
false
false
false
France
French
treatment outcome
glycerol phenylbutyrate
glycerol phenylbutyrate
urea cycle disorders, inborn
adult
adolescent
child
infant
carbamoyl-phosphate synthase i deficiency disease
ornithine carbamoyltransferase deficiency disease
argininosuccinic aciduria
hyperargininemia
citrullinemia
HHH syndrome
administration, oral
Enteral Route of Administration
Gastroenteral route (qualifier value)
evaluation of the transparency committee
guidelines for drug use
ornithine
hyperammonemia
phenylbutyrates
glycerol
glycerol
---
https://www.ema.europa.eu/medicines/human/EPAR/Ravicti
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
orphan drug production
glycerol phenylbutyrate
glycerol phenylbutyrate
glycerol phenylbutyrate
urea cycle disorders, inborn
adult
adolescent
child
infant
carbamoyl-phosphate synthase i deficiency disease
ornithine carbamoyltransferase deficiency disease
argininosuccinic aciduria
hyperargininemia
citrullinemia
HHH syndrome
continuity of patient care
administration, oral
Enteral Route of Administration
product surveillance, postmarketing
Gastroenteral route (qualifier value)
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ornithine
hyperammonemia
phenylbutyrates
glycerol
glycerol
phenylbutyrates
glycerol
---
http://www.cochrane.org/fr/CD007547
2011
false
true
false
United Kingdom
France
treatment outcome
phenylbutyrates
phenylbutyrates
Product containing fenbufen in oral dose form (medicinal product form)
administration, oral
review of literature
french abstract
adult
pain, postoperative
fenbufen
acute pain
---
http://www.has-sante.fr/portail/display.jsp?id=c_241518
2001
France
French
phenylbutyrates
antineoplastic agents
4-phenylbutyric acid
sodium phenylbutyrate
4-phenylbutyric acid, sodium salt
guidelines for drug use
---
http://www.has-sante.fr/portail/display.jsp?id=c_241518
2001
France
French
antineoplastic agents
phenylbutyrates
ornithine carbamoyltransferase deficiency disease
child
carbamoyl-phosphate synthase (ammonia)
argininosuccinate synthase
citrullinemia
infant, newborn
ornithine carbamoyltransferase
infant
sodium phenylbutyrate
4-phenylbutyric acid, sodium salt
4-phenylbutyric acid
evaluation of the transparency committee
---